Identification of osimertinib-resistant <i>EGFR</i> L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort.

导出 OA

翻译打印收藏纠错

作者： Stephen R,Fairclough ^[1] ; Lesli A,Kiedrowski ^[1] ; Jessica J,Lin ^[2] ; Ori,Zelichov ^[3] ; Gabi,Tarcic ^[3] ; Thomas E,Stinchcombe ^[4] ; Justin I,Odegaard ^[1] ; Richard B,Lanman ^[1] ; Alice T,Shaw ^[2] ; Rebecca J,Nagy ^[1]

作者单位： Guardant Health, Inc., 505 Penobscot Dr, Redwood City, CA 94063 USA. ^[1] 2Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114 USA. ^[2] NovellusDx, Jerusalem Biopark, Hadassah Ein-Kerem Medical Center Campus, Jerusalem, Israel. ^[3] 4Duke Cancer Institute, DUMC 3198, 25178 Morris Building, Durham, NC 27710 USA. ^[4]

关键词 Acquired resistance Cell-free DNA Functional studies Genomic evolution Guardant360 Osimertinib cfDNA

DOI 10.1186/s40164-019-0148-7

PMID 31632838

发布时间 2020-09-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Experimental hematology & oncology

2019年8卷

24页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Identification of osimertinib-resistant <i>EGFR</i> L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort.

Experimental hematology & oncology

相似文献

Experimental hematology & oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Identification of osimertinib-resistant <i>EGFR</i> L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort.

Experimental hematology & oncology

相似文献

Experimental hematology & oncology

相关期刊

检索历史清除